In vivo and in vitro characteristics for insulin-loaded PLA microparticles prepared by w/o/w solvent evaporation method with electrolytes in the continuous phase.
Insulin-loaded poly(lactide) (PLA) microparticles were successfully prepared by 6% w/v PLA in the organic phase, 10% w/v PVP and varied types of 5%w/v electrolytes in the continuous phase, by using a water-in-oil-in-water emulsion/ solvent extraction technique. Addition of electrolytes such as NaCl, CaCl2 into the external phase significantly improved insulin entrapment efficiency compared to the case of no additives. NaCl was the most effective for obtaining high entrapment efficiency, with microparticle yield 81.2%, trapping efficiencies 49%, insulin-loading level 5.5% w/w and mean particle size 14.8 microm. The distribution (%) of insulin on the PLA microparticles surface, outer layer and core were 8, 37 and 43%, respectively. The cumulative release of insulin had an upper limit of approximately 24% of the insulin load at 24 days. A steady release rate was 0.5 microg insulin/mg microparticles/day of insulin release maintained for 24 days. Total protein-leaking amount was reduced after addition of electrolytes in the continuous aqueous phase. Rabbit glucose levels were evaluated after subcutaneous 20 mg insulin-loaded PLA microparticles or PLA blank microparticles. Study results show that the insulin-loaded PLA microparticles significantly reduced the glucose level than PLA blank microparticles. The insulin-loaded PLA microparticles, physicochemical characterization data and the animal result obtained in this study may be relevant in optimizing the PLA microparticle formulation incorporation and delivery insulin carriers.
Yeh
M K
MK
Department of Clinical Pharmacy, Tri-service General Hospital, National Defence Medical Center, Neihu, Taipei (114), Taiwan. mkyeh@mail.ndmctsgh.edu.tw
Chen
J L
JL
Chiang
C H
CH
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D003692:Delayed-Action Preparations; D004339:Drug Compounding / Q000379:methods; D004573:Electrolytes; D007004:Hypoglycemic Agents / Q000097:blood / Q000493:pharmacokinetics*; D007328:Insulin / Q000097:blood / Q000493:pharmacokinetics*; D008297:Male; D008863:Microspheres; D011091:Polyesters; D011817:Rabbits; D011897:Random Allocation
D001786:Blood Glucose; D003692:Delayed-Action Preparations; D004573:Electrolytes; D007004:Hypoglycemic Agents; D007328:Insulin; D011091:Polyesters; C033616:poly(lactide)